

# ForPatients

*by Roche*

Diffuse Large B-Cell Lymphoma (DLBCL)

## **A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma**

**Trial Status**

Active, not recruiting

**Trial Runs In**

23 Countries

**Trial Identifier**

NCT03274492 2017-002023-21  
GO39942

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

**NCT03274492 2017-002023-21 GO39942**

Trial Identifiers

### ***Eligibility Criteria:***

**Gender**

All

**Age**

>= 18 Years & <= 80 Years

**Healthy Volunteers**

No